Tecentriq (Atezolizumab) vs Ibrance (palbociclib)
Tecentriq (Atezolizumab) vs Ibrance (palbociclib)
Tecentriq (atezolizumab) is an immune checkpoint inhibitor specifically designed to target and inhibit the protein PD-L1, which is used primarily in the treatment of certain types of lung cancer, bladder cancer, and triple-negative breast cancer. Ibrance (palbociclib), on the other hand, is a CDK4/6 inhibitor that is used to treat HR-positive, HER2-negative breast cancer, typically in combination with hormonal therapies. The choice between Tecentriq and Ibrance would depend on the specific type and characteristics of the cancer being treated, as well as the patient's overall health, treatment goals, and potential side effects, and should be made in consultation with an oncologist.
Difference between Tecentriq and Ibrance
Metric | Tecentriq (Atezolizumab) | Ibrance (palbociclib) |
---|---|---|
Generic name | Atezolizumab | Palbociclib |
Indications | Urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, hepatocellular carcinoma, and others | Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer |
Mechanism of action | PD-L1 inhibitor, immune checkpoint inhibitor that helps the body’s immune system attack cancer cells | CDK4/6 inhibitor, inhibits cyclin-dependent kinases 4 and 6 to prevent cell division and growth of cancer cells |
Brand names | Tecentriq | Ibrance |
Administrative route | Intravenous infusion | Oral |
Side effects | Fatigue, decreased appetite, nausea, urinary tract infection, fever, and others | Neutropenia, leukopenia, infections, fatigue, nausea, anemia, and others |
Contraindications | None specifically listed; use with caution in patients with pre-existing liver or lung conditions | Hepatic impairment, existing neutropenia, concurrent use with strong CYP3A inhibitors or inducers |
Drug class | Monoclonal antibody, immune checkpoint inhibitor | CDK4/6 inhibitor, antineoplastic agent |
Manufacturer | Genentech (a member of the Roche Group) | Pfizer |
Efficacy
Efficacy of Tecentriq (Atezolizumab) in Breast Cancer
Tecentriq (Atezolizumab) is an immune checkpoint inhibitor that has shown efficacy in the treatment of triple-negative breast cancer (TNBC), a particularly aggressive form of breast cancer that lacks estrogen receptors, progesterone receptors, and excess HER2 protein. Atezolizumab is designed to target and inhibit the protein PD-L1, which can be expressed on the surface of tumor cells or immune cells in the tumor environment. By blocking PD-L1, Tecentriq is intended to enable the activation of T-cells and the body's natural immune response to target and destroy cancer cells.
The efficacy of Tecentriq in breast cancer was demonstrated in the IMpassion130 trial, a phase III study that evaluated the drug in combination with nab-paclitaxel in patients with previously untreated metastatic triple-negative breast cancer. The study showed that the addition of Tecentriq to chemotherapy significantly extended progression-free survival in patients whose tumors expressed PD-L1 compared to chemotherapy alone. This benefit was particularly pronounced in the PD-L1 positive population, leading to Tecentriq's approval for use in this subset of breast cancer patients.
Efficacy of Ibrance (Palbociclib) in Breast Cancer
Ibrance (Palbociclib) is an oral medication used in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Palbociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which are proteins that regulate cell division. By inhibiting these kinases, Ibrance can help to stop cancer cells from proliferating.
The efficacy of Ibrance has been evaluated in several pivotal clinical trials, including the PALOMA-1, PALOMA-2, and PALOMA-3 studies. These trials have consistently shown that when used in combination with hormonal therapies such as letrozole or fulvestrant, Ibrance significantly improves progression-free survival compared to hormonal therapy alone. The improvement in progression-free survival has made Ibrance a standard of care in the first-line and subsequent lines of treatment for HR+, HER2- advanced or metastatic breast cancer. However, it should be noted that while Ibrance has been shown to delay disease progression, an increase in overall survival has not been definitively established for all patient populations.
Regulatory Agency Approvals
Tecentriq
Ibrance
Access Tecentriq or Ibrance today
If Tecentriq or Ibrance are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us